Daily Roundup

NEU.ASX SDV.ASX MYE.ASX EQR.ASX LNW.ASX

Neuren Pharmaceuticals is riding high on the back of record quarterly sales. The company's flagship drug DAYBUE hit US$125 million in Q2 net sales, marking a solid 30% jump from the same period last year. The real driver here is DAYBUE STIX, a new powder formulation that's resonating with patients—by the end of Q2, about 40% of all US DAYBUE patients had switched to it. Looking ahead, Neuren is gearing up for a European launch in Q4 2026 after receiving a positive recommendation from regulators in June. Japan trial results are also on the horizon, expected sometime between September and November, with a regulatory submission anticipated in 2027. The company's royalty income clocked in at US$12.9 million for the quarter, and management has upgraded its full-year guidance based on stronger-than-expected demand.

SciDev is making its first real push into Australia's booming data centre market. The company has landed initial contracts with two of the country's largest hyperscale data centre operators and developers, covering design, consulting, and embedded engineering services. These deals are expected to bring in around $0.5 million in revenue during the first half of FY27, but management sees real potential for these relationships to expand down the track.

Mastermyne Group has secured a major mining services contract that could be worth up to $255 million over six years. The deal with GM3 covers the Dendrobium underground coal mine in New South Wales and includes an initial two-year term worth approximately $85 million in gross revenues. Two additional two-year extension options are also on the table. The contract will create more than 140 new jobs and builds on Mastermyne's existing presence at the site. The company is entering FY27 with a strong order book and a healthy pipeline of opportunities, buoyed by sustained demand for specialist underground coal mining services.

EQ Resources delivered a standout performance in July, posting record revenue of A$51 million as production ramped up across its operations. Consolidated production jumped 36% month-on-month to 14,255 mtu, while the company achieved a record average realised price of US$2,386 per mtu. The Barruecopardo site was particularly impressive, notching its highest monthly production since December 2025 with a 48% increase, while Mt Carbine also chipped in with a 16% production lift.

Light & Wonder wrapped up Q2 with results that show the gaming and iGaming operator is firing on multiple cylinders. Net income climbed 26% to $120 million, while consolidated AEBITDA rose 9% to $383 million. Revenue came in at $828 million, up 2% year-over-year, with Gaming operations and iGaming both contributing to the growth. Recurring revenue hit $580 million, a 6% increase, and adjusted free cash flow surged 50% to $156 million. The company returned $134 million to shareholders through buybacks and maintained its full-year 2026 guidance, expecting mid- to high-single-digit growth in consolidated AEBITDA. Management remains focused on reducing net debt leverage below 3.0x during the first half of 2027.